FDA Oncology Drug Approvals Granted Between May 21, 2018 and May 14, 2019


Jun 3, 2019 - Many important drugs for the treatment of cancer were approved by the FDA from the period of May 21 2018 to May 14 2019. Of note is Tecentriq which was approved in March 2018 and Talzenna in October 2018, both for locally advanced or metastatic TNBC. However, in the case of Tecentriq, only tumors with the PD-L1 marker were likely to respond and for Talzenna, only women with a BRCA mutation are eligible for treatment. These criteria means that most women diagnosed with TNBC are still not able to access these treatments because PD-L1 expression and BRCA mutations are only found in small subsets of women with TNBC. As there are no targeted therapies available for most TNBC, it remains a major unmet medical need.

Read the full article here

Keytruda Fails to Improve Overall Survival of Patients with Triple-Negative Breast Cancer, Phase 3 Trial Shows


May 24, 2019 - Disappointing news has just been just released about the promising new immunotherapy drug pembrolizumab (Keytruda), that did not show any overall survival advantage over conventional chemotherapy treatment in women with metastatic TNBC. There remains limited options for women diagnosed with this aggressive type of breast cancer, therefore it is imperative we keep working towards an effective targeted therapy for TNBC.

Read more here

Atezolizumab (Tecentriq) Approved for Some Patients with Triple-Negative Breast Cancer


Mar 28, 2019 - Accelerated approval for the use of Tecentriq, an immunotherapy drug, in combination with chemotherapy was granted for use in a specific subset of women with locally advanced or metastatic TNBC, whose tumor expressed the marker PD-L1, and who could not undergo surgery. However, there is a large population of women with TNBC tumors that do not express PD-L1, therefore we need to keep working on developing a targeted therapy that will be able help more women with TNBC.

Read the full article here

Market outlook for the therapeutic market in TNBC in G8 Countries is expected to increase at a compound annual growth rate of 18.9% by 2027


Oct 30, 2018 - A comprehensive forecast report by DelveInsight ( a business consultant & market research firm) into the future of the TNBC market from 2016 - 2027, shows that there is plenty of room for growth in the therapeutics field for this disease.

Read more about the report here

RSK Potentially Possesses a Safer Toxicity Profile Than the Competition - A Patent Review

July 13, 2016 - Expert key opinion leader Dr. Deborah A. Lannigan from Vanderbilt University recently published "that targeting the downstream effectors of MEK1/2, like RSK, are an untapped source of drug targets and that they will generate less side effects than MEK1/2 inhibitors because they regulated fewer effectors". She went on to mention that "based on overwhelming evidence that RSK is involved in a number of diseases that have high moralities it seems surprising that there are no RSK modulators that have pharmacokinetic properties suitable for in vivo use". Read the abstract here

Biotech Industry Gaining Popularity Among Venture Capital Asset Classes

Forbes - August 1, 2016 - "Biotech has been one of the hottest sectors in the venture capital asset class over the past new years. Strong IPO and M&A markets have put wind in the sails of the space since 2012, and robust investment activity has enabled a wave of well-funded biotechs to mature with a lower cost of capital than a decade ago.

Read full article here...